Results 61 to 70 of about 15,404 (212)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh +2 more
wiley +1 more source
, 2023 Yuming Wang,1,2,* Yunting Zhou,2,* Xiao Zhou,2,* Xiaofei Su,2,* Xiaohua Xu,2 Huiqin Li,2 Jianhua Ma2 1Department of Geriatrics, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008 ...
Li H +6 more
core
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes [PDF]
Diabetes & Metabolism Journal, 2014 BackgroundWe evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus.MethodsA total of 170 type 2 diabetes patients treated with sitagliptin ...
Eun Yeong Choe +10 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland.
Atte Vaden +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim +9 more
wiley +1 more source
Sitagliptin improves insulin production.
, 2013 (A) Insulin content of islet grafts transplanted to the kidney capsule given asµg insulin per g kidney. Control = normal chow, Sitagliptin = 5.5% sitagliptin included into the rodent chow (p < 0.05; n = 6). (B) Insulin area (μm2) of sections of mouse
Neelam Lingwal (183259) +5 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean ...
Chungsoo Kim +5 more
wiley +1 more source
Neurobiology of Disease, 2012 Increasing evidence supports an association between Alzheimer's disease (AD) and diabetes. In this context, anti-diabetic agents such as rosiglitazone and glucagon-like peptide (GLP)-1 have been reported to reduce pathologies associated with AD ...
Dong-Hou Kim +6 more
doaj +1 more source
Obesity Reviews, EarlyView.ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh +14 more
wiley +1 more source
Obesity Reviews, EarlyView.ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira +8 more
wiley +1 more source